Skip to main content

Table 2 Univariable and multivariable analyses for PFS data

From: Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

  mPFS HR univariable
(95% CI)
p-value HR multivariable (95% CI) p-value
Entire cohort (95% CI) 5.2 (3.4–7.0)      
Age ≤ 65 3.3      
Age > 65 7.7 0.66 (0.40–1.09) 0.113 0.64 (0.37–1.10) 0.108
Locally advanced 6.8      
Metastasized 4.5 1.22 (0.72–2.09) 0.434 1.55 (0.80–2.98) 0.190
ECOG PS 0 6.2      
ECOG PS 1–2 4.5 1.08 (0.65–1.79) 0.769 1.16 (0.68–2.00) 0.579
Ca19–9 < mediana 5.4      
Ca19–9 > median 5.1 1.15 (0.68–1.96) 0.597   
Ca19–9 < 59xULN 4.2     
Ca19–9 ≥ 59xULN 6.4 1.43 (0.82–2.49) 0.228   
Albumin ≤37 5.1      
Albumin > 37 6.1 0.72 (0.44–1.19) 0.194 0.93 (0.53–1.67) 0.826
TPK grade 0 3.1      
TPK grade 1–4 7.0 0.31 (0.18–0.55) < 0.001 0.49 (0.26–0.93) 0.029
Normal bilirubinb 5.2      
Elevated bilirubin 4.0 1.56 (0.56–4.34) 0.482   
Dose reduction 6.4      
Full dose 3.0 2.10 (1.13–3.93) 0.045 1.15 (0.57–2.33) 0.698
BM-tox grade 0–1 4.2      
BM-tox grade 2–4 6.8 0.50 (0.29–0.85) 0.021   
BM-tox grade 0–2 5.1      
BM-tox grade 3–4 6.2 0.41 (0.20–0.87) 0.137 0.80 (0.41–1.56) 0.506
No leucocytosisc 4.5      
Leucocytosis 6.5 0.96 (0.57–1.63) 0.886   
  1. Median PFS in months. aMedian CA19–9 was 567kU/l, bS-bil < 26 μmole/L at treatment start, c < 8.8 × 109/L at treatment start
\